436 related articles for article (PubMed ID: 17070129)
1. New 19-nor-(20S)-1alpha,25-dihydroxyvitamin D3 analogs strongly stimulate osteoclast formation both in vivo and in vitro.
Sato M; Nakamichi Y; Nakamura M; Sato N; Ninomiya T; Muto A; Nakamura H; Ozawa H; Iwasaki Y; Kobayashi E; Shimizu M; DeLuca HF; Takahashi N; Udagawa N
Bone; 2007 Feb; 40(2):293-304. PubMed ID: 17070129
[TBL] [Abstract][Full Text] [Related]
2. c-Fos protein as a target of anti-osteoclastogenic action of vitamin D, and synthesis of new analogs.
Takasu H; Sugita A; Uchiyama Y; Katagiri N; Okazaki M; Ogata E; Ikeda K
J Clin Invest; 2006 Feb; 116(2):528-35. PubMed ID: 16424941
[TBL] [Abstract][Full Text] [Related]
3. Osteoblastic NF-κB pathway is involved in 1α, 25(OH)2D3-induced osteoclast-like cells formation in vitro.
Cong L; Zhang C; Tu G
Int J Clin Exp Pathol; 2015; 8(5):5988-96. PubMed ID: 26191332
[TBL] [Abstract][Full Text] [Related]
4. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function.
Udagawa N; Takahashi N; Yasuda H; Mizuno A; Itoh K; Ueno Y; Shinki T; Gillespie MT; Martin TJ; Higashio K; Suda T
Endocrinology; 2000 Sep; 141(9):3478-84. PubMed ID: 10965921
[TBL] [Abstract][Full Text] [Related]
5. The Vitamin D Receptor in Osteoblast-Lineage Cells Is Essential for the Proresorptive Activity of 1α,25(OH)2D3 In Vivo.
Mori T; Horibe K; Koide M; Uehara S; Yamamoto Y; Kato S; Yasuda H; Takahashi N; Udagawa N; Nakamichi Y
Endocrinology; 2020 Nov; 161(11):. PubMed ID: 32987399
[TBL] [Abstract][Full Text] [Related]
6. Alisol-B, a novel phyto-steroid, suppresses the RANKL-induced osteoclast formation and prevents bone loss in mice.
Lee JW; Kobayashi Y; Nakamichi Y; Udagawa N; Takahashi N; Im NK; Seo HJ; Jeon WB; Yonezawa T; Cha BY; Woo JT
Biochem Pharmacol; 2010 Aug; 80(3):352-61. PubMed ID: 20412788
[TBL] [Abstract][Full Text] [Related]
7. A potent analog of 1alpha,25-dihydroxyvitamin D3 selectively induces bone formation.
Shevde NK; Plum LA; Clagett-Dame M; Yamamoto H; Pike JW; DeLuca HF
Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13487-91. PubMed ID: 12374862
[TBL] [Abstract][Full Text] [Related]
8. The development of a bone- and parathyroid-specific analog of vitamin D: 2-methylene-19-Nor-(20S)-1α,25-dihydroxyvitamin D3.
Deluca HF
Bonekey Rep; 2014; 3():514. PubMed ID: 24818006
[TBL] [Abstract][Full Text] [Related]
9. 2-Methylene-19-nor-(20S)-1,25-dihydroxyvitamin D3 potently stimulates gene-specific DNA binding of the vitamin D receptor in osteoblasts.
Yamamoto H; Shevde NK; Warrier A; Plum LA; DeLuca HF; Pike JW
J Biol Chem; 2003 Aug; 278(34):31756-65. PubMed ID: 12796488
[TBL] [Abstract][Full Text] [Related]
10. 1,25-Dihydroxyvitamin D3 stimulates cyclic vitamin D receptor/retinoid X receptor DNA-binding, co-activator recruitment, and histone acetylation in intact osteoblasts.
Kim S; Shevde NK; Pike JW
J Bone Miner Res; 2005 Feb; 20(2):305-17. PubMed ID: 15647825
[TBL] [Abstract][Full Text] [Related]
11. Microrough implant surface topographies increase osteogenesis by reducing osteoclast formation and activity.
Lossdörfer S; Schwartz Z; Wang L; Lohmann CH; Turner JD; Wieland M; Cochran DL; Boyan BD
J Biomed Mater Res A; 2004 Sep; 70(3):361-9. PubMed ID: 15293309
[TBL] [Abstract][Full Text] [Related]
12. Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3.
Skowronski RJ; Peehl DM; Feldman D
Endocrinology; 1995 Jan; 136(1):20-6. PubMed ID: 7530193
[TBL] [Abstract][Full Text] [Related]
13. Analogs of 1alpha,25-dihydroxyvitamin D3 with high potency in induction of osteoclastogenesis and prevention of dendritic cell differentiation: synthesis and biological evaluation of 2-substituted 19-norvitamin D analogs.
Shimazaki M; Miyamoto Y; Yamamoto K; Yamada S; Takami M; Shinki T; Udagawa N; Shimizu M
Bioorg Med Chem; 2006 Jul; 14(13):4645-56. PubMed ID: 16513359
[TBL] [Abstract][Full Text] [Related]
14. Altered pharmacokinetics of 1alpha,25-dihydroxyvitamin D3 and 25-hydroxyvitamin D3 in the blood and tissues of the 25-hydroxyvitamin D-24-hydroxylase (Cyp24a1) null mouse.
Masuda S; Byford V; Arabian A; Sakai Y; Demay MB; St-Arnaud R; Jones G
Endocrinology; 2005 Feb; 146(2):825-34. PubMed ID: 15498883
[TBL] [Abstract][Full Text] [Related]
15. [Effects of 1,25-dihydroxyvitamin D3 on the expressions of osteoprotegerin and receptor activator of NF-kappaB ligand in mouse osteoblasts].
Tian QX; Huang GY
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Aug; 26(4):418-22. PubMed ID: 15379268
[TBL] [Abstract][Full Text] [Related]
16. (23S)-25-Dehydro-1{alpha}-hydroxyvitamin D3-26,23-lactone, a vitamin D receptor antagonist that inhibits osteoclast formation and bone resorption in bone marrow cultures from patients with Paget's disease.
Ishizuka S; Kurihara N; Reddy SV; Cornish J; Cundy T; Roodman GD
Endocrinology; 2005 Apr; 146(4):2023-30. PubMed ID: 15618361
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of inhibitory action of eldecalcitol, an active vitamin D analog, on bone resorption in vivo.
Takahashi N
J Steroid Biochem Mol Biol; 2013 Jul; 136():171-4. PubMed ID: 23220095
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and structure-activity relationships of 16-ene-22-thia-1alpha,25-dihydroxy-26,27-dimethyl-19-norvitamin D3 analogs having side chains of different sizes.
Takaku H; Miyamoto Y; Asami S; Shimazaki M; Yamada S; Yamamoto K; Udagawa N; DeLuca HF; Shimizu M
Bioorg Med Chem; 2008 Feb; 16(4):1796-815. PubMed ID: 18032055
[TBL] [Abstract][Full Text] [Related]
19. Vitamin D hormone inhibits osteoclastogenesis in vivo by decreasing the pool of osteoclast precursors in bone marrow.
Shibata T; Shira-Ishi A; Sato T; Masaki T; Masuda A; Hishiya A; Ishikura N; Higashi S; Uchida Y; Saito MO; Ito M; Ogata E; Watanabe K; Ikeda K
J Bone Miner Res; 2002 Apr; 17(4):622-9. PubMed ID: 11918219
[TBL] [Abstract][Full Text] [Related]
20. Novel vitamin D3 analogs, 1alpha, 25(OH)2D(3)-26, 23-lactam (DLAMs), antagonize bone resorption via suppressing RANKL expression in osteoblasts.
Inada M; Tsukamoto K; Hirata M; Takita M; Nagasawa K; Miyaura C
Biochem Biophys Res Commun; 2008 Aug; 372(3):434-9. PubMed ID: 18489902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]